Floatz logo

Rapamycin

Myelogenous Leukemia

Masonic Cancer Center, University of MinnesotaPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

31 Active assets in the Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
M.D. Anderson Cancer Center
Phase 2/3BBB
Cyclophosphamide
Actinium Pharmaceuticals
Phase 2/3BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 2BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 3BB
TACROLIMUS
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB

View all 50 →

Same molecule, other indications

Rapamycin is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →